AR061369A1 - PIRIMIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND THEM - Google Patents
PIRIMIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND THEMInfo
- Publication number
- AR061369A1 AR061369A1 ARP070102594A ARP070102594A AR061369A1 AR 061369 A1 AR061369 A1 AR 061369A1 AR P070102594 A ARP070102594 A AR P070102594A AR P070102594 A ARP070102594 A AR P070102594A AR 061369 A1 AR061369 A1 AR 061369A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- heterocyclyl
- alkynyl
- alkenyl
- independently selected
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Estos compuestos proporcionan un tratamiento o profilaxis para el deterioro cognitivo, la enfermedad de Alzheimer, la neurodegeneracion y la demencia. Reivindicacion 1: Un compuesto de formula 1: donde A se selecciona independientemente entre un anillo heterocíclico de 5, 6 o 7 miembros opcionalmente sustituido con uno o más R1; B se selecciona independientemente entre fenilo o entre un anillo heteroaromático de 5 o 6 miembros opcionalmente sustituido con uno o más R2, C se selecciona independientemente entre fenilo o un anillo heteroaromático de 5 o 6 miembros opcionalmente sustituido con uno o más R3; R1 se selecciona independientemente entre halogeno, ciano, nitro, OR6, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, alquilC0- 6arilo, alquilC0-6heteroarilo, alquilC0-6-cicloalquilo C3-6, alquil C0-6-cicloalquenilo C3-6, alquil C0-6-cicloalquinilo C3-6, alquil C0-6-heterociclilo C3-6, NR6R7, CONR6R7, NR6(CO)R7, O(CO)R6, CO2R6, COR6, (SO2)NR6R7, NR6(SO2)R7, SOR6, SO2R6, OSO2R6 y SO3R6 donde dicho alquilo C1-6, alquenilo C2-6, alquinilo C2-6, alquilC0-6arilo, alquilC0-6heteroarilo, alquil C0-6-cicloalquilo C3-6, alquil C0-6-cicloalquenilo C3-6, alquil C0-6-cicloalquinilo C3-6 y alquil C0-6 heterociclilo C3-6 está opcionalmente sustituido con uno o más E; o dos sustituyentes R1 junto con el átomo al cual están unidos, forman un anillo cíclico o heterocíclico opcionalmente sustituido con uno o más E; R2, R3 o R4 se selecciona entre arilo, heteroarilo, cicloalquenilo C3-6, cicloalquinilo C3-6, heterociclilo C3-6, CONR6R7, NR6(CO)R7, O(CO)R6, CO2R6, COR6, (SO2)NR6R7, NR6(SO2)R7, SOR6, SO2R6, OSO2R6 y SO3R6 donde dicho arilo, heteroarilo, cicloalquenilo C3-6, cicloalquinilo C3-6 y heterociclilo C3-6 puede estar opcionalmente sustituido con uno o más E; R5se selecciona independientemente entre hidrogeno, ciano, OR6, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, alquilC0-6arilo, alquilC0-6heteroarilo, alquil C0-6-cicloalquilo C3-6, alquil C0-6- cicloalquenilo C3-6, alquil C0-6-cicloalquinilo C3-6, alquiI C0-6heterociclilo C3-6, CONR6R7, CO2R6, COR6, SO2R6 y SO3R6 donde dicho alquiIo C1-6, alquenilo C2-6, aIquinilo C2-6, alquilC0-6arilo, alquilC0-6heteroarilo, alquil C0-6-cicloalquilo C3-6, alquiI C0-6-cicloalquenilo C3-6, alquil C0-6-cicloalquinilo C3-6, alquil C0-6-heterociclilo C3-6 puede estar opcionalmente sustituido con uno o más E; E se selecciona independientemente entre halogeno, nitro, CN, OR6, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, alquilC0-6arilo, alquilC0-6heteroarilo, alquil C0-6-cicloalquilo C3-6, alquil C0-6-cicloalquenilo C3-6, alquil C0-6-cicloalquinilo C3-6, alquil C0-6-heterociclilo, fluormetilo, difluormetilo, trifluormetilo, fluorrnetoxi, difluormetoxi, trifluormetoxi, NR6R7, CONR6R7, NR6(CO)R7, O(CO)R6, CO2R6, COR6, (SO2)NR6R7, NR6SO2R7, SO2R6, SOR6, OSO2R6 y SO3R6, donde dicho alquilo C1-6, alquenilo C2-6, alquinilo C2-6, alquilC0-6arilo, alquilC0-6heteroarilo, alquil C0-6- cicloalquilo C3-6, alquil C0-6-cicloalquenilo C3-6, alquil C0-6-cicloalquinilo C3-6 o alquilC0-6heterociclilo puede estar opcionalmente sustituido con uno o más sustituyentes seleccionados independientemente entre halo, nitro, ciano, OR6, alquiIo C1- 6, fluormetilo, difluormetilo, trifluormetilo, fluormetoxi, difluormetoxi y trifluormetoxi; R6 y R7 se seleccionan independientemente entre hidrogeno, alquilo C1-6, fluormetilo, difluormetilo, trifluormetilo, alquenilo C2-6, alquinilo C2-6, alquilC0- 6arilo, alquilC0-6heteroarilo, alquil C0-6-cicloalquilo C3-6, alquil C0-6cicloalquenilo C3-6, aIquil C0-6-cicloalquinilo C3-6, alquilC0-6heterociclilo, o R6 y R7 pueden formar en forma conjunta un anillo heterocíclico de 5 o 6 miembros que contiene uno o más heteroátomos seleccionados entre N, O o S; R8 se selecciona independientemente entre halogeno, ciano, nitro, OR9, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, alquilC0-6arilo, alquilC0-6heteroarilo, alquil C0-6-cicloalquilo C3-6, alquil C0-6-cicloalquenilo C3-6, alquil C0-6-cicloalquinilo C3-6, alquil C0-6-heterociclilo C3-6, NR9R10, CONR9R10, NR9(CO)R10, O(CO)R9, CO2R9, COR9, (SO2)NR9R10, NR9(SO2)R10, SO2R9, SOR9, OSO2R9 y SO3R9 donde dicho alquilo C1-6, alquenilo C2-6, alquinilo C2-6, alquilC0-6arilo, alquilC0-6heteroarilo, alquil C0-6-cicloalquilo C3-6, alquil C0-6-cicloalquenilo C3-6, alquil C0-6-cicloalquinilo C3-6 y alquil C0-6-heterociclilo C3-6 pueden estar opcionalmente sustituidos con uno o más E; o dos R8 pueden junto con los átomos a los cuales están unidos formar un anillo cíclico o heterocíclico opcionalmente sustituido con uno o más E; R9 y R10 se seleccionan independientemente entre hidrogeno, alquilo C1-6, fluormetilo, difluormetilo, trifluormetilo, alquenilo C2-6, alquinilo C2-6, alquilC0-6arilo, alquilC0-6heteroarilo, alquil C0-6-cicloalquilo C3-6, alquil C0-6-cicloalquenilo C3-6, alquil C0-6-cicloalquinilo C3-6, alquilC0-6heterociclilo; o R9 y R10 pueden formar en forma conjunta un anillo heterocíclico de 5 o 6 miembros que contiene uno o más heteroátomos seleccionados entre N, O o S; m= 0,1 o 2; n= 0,1, 2 o 3 p= 0,1, 2 o 3; q= 0,1, 2 o 3; t= 0, 1, 2 o 3; donde uno de n, p o q es por lo menos 1; como una base libre o una sal, solvato o solvato de una sal del mismo aceptable para uso farmacéutico.These compounds provide a treatment or prophylaxis for cognitive impairment, Alzheimer's disease, neurodegeneration and dementia. Claim 1: A compound of formula 1: wherein A is independently selected from a 5-, 6- or 7-membered heterocyclic ring optionally substituted with one or more R1; B is independently selected from phenyl or from a 5- or 6-membered heteroaromatic ring optionally substituted with one or more R2, C is independently selected from phenyl or a 5 or 6-membered heteroaromatic ring optionally substituted with one or more R3; R1 is independently selected from halogen, cyano, nitro, OR6, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C0-6alkyl, C0-6 alkyl heteroaryl, C0-6 alkylC3-6 alkyl, C0-6 alkyl C3-6 cycloalkenyl, C0-6 alkyl C3-6 cycloalkynyl, C0-6 alkyl heterocyclyl C3-6, NR6R7, CONR6R7, NR6 (CO) R7, O (CO) R6, CO2R6, COR6, (SO2) NR6R7, NR6 (SO2) R7, SOR6, SO2R6, OSO2R6 and SO3R6 wherein said C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C0-6alkyl, C0-6heteroaryl, C0-6-C3-6 alkyl, C0 alkyl -6-C3-6 cycloalkenyl, C0-6 alkyl C3-6 alkyl and C0-6 alkyl C3-6 heterocyclyl optionally is substituted with one or more E; or two R1 substituents together with the atom to which they are attached, form a cyclic or heterocyclic ring optionally substituted with one or more E; R2, R3 or R4 is selected from aryl, heteroaryl, C3-6 cycloalkenyl, C3-6 cycloalkynyl, C3-6 heterocyclyl, CONR6R7, NR6 (CO) R7, O (CO) R6, CO2R6, COR6, (SO2) NR6R7, NR6 (SO2) R7, SOR6, SO2R6, OSO2R6 and SO3R6 wherein said aryl, heteroaryl, C3-6 cycloalkenyl, C3-6 cycloalkynyl and C3-6 heterocyclyl may be optionally substituted with one or more E; R5 is independently selected from hydrogen, cyano, OR6, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C0-6 alkyl, C0-6heteroaryl, C0-6 alkylC3-6 alkyl, C0-6-cycloalkenyl alkyl -6, C0-6 alkyl C3-6 alkyl, C0-6 alkyl C3-6 heterocyclyl, CONR6R7, CO2R6, COR6, SO2R6 and SO3R6 wherein said C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C0-6 alkyl , C0-6 alkyl heteroaryl, C0-6 alkyl C3-6 alkyl, C0-6 alkyl C3-6 alkyl, C0-6 alkyl C3-6 cycloalkynyl, C0-6 alkyl C3-6 heterocyclyl may be optionally substituted with one or more E; E is independently selected from halogen, nitro, CN, OR6, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C0-6 alkyl, C0-6 alkyl heteroaryl, C0-6 alkylC3-6 alkyl, C0-6 alkyl C3-6cycloalkenyl, C0-6 alkyl C3-6 alkyl, C0-6 alkyl heterocyclyl, fluoromethyl, difluoromethyl, trifluoromethyl, fluorrnethoxy, difluoromethoxy, trifluoromethoxy, NR6R7, CONR6R7, NR6 (CO) R7, O (CO) R7, O (CO) R7, O (CO) R7, O (CO) R7 , CO2R6, COR6, (SO2) NR6R7, NR6SO2R7, SO2R6, SOR6, OSO2R6 and SO3R6, wherein said C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C0-6aryl, C0-6henylaryl, C0-6- alkyl C3-6 cycloalkyl, C0-6 alkyl C3-6 cycloalkenyl, C0-6 alkyl C3-6 cycloalkynyl or C0-6 alkyl heterocyclyl may be optionally substituted with one or more substituents independently selected from halo, nitro, cyano, OR6, C1 alkyl - 6, fluormethyl, difluoromethyl, trifluoromethyl, fluoromethoxy, difluoromethoxy and trifluoromethoxy; R6 and R7 are independently selected from hydrogen, C1-6 alkyl, fluoromethyl, difluoromethyl, trifluoromethyl, C2-6 alkenyl, C2-6 alkynyl, C0-6aryl alkyl, C0-6heteroaryl alkyl, C0-6 alkylC3-6 alkyl, C0 alkyl -6 C3-6cycloalkenyl, C0-6 alkyl-C3-6 cycloalkynyl, C0-6 alkyl heterocyclyl, or R6 and R7 can together form a 5 or 6 membered heterocyclic ring containing one or more heteroatoms selected from N, O or S ; R8 is independently selected from halogen, cyano, nitro, OR9, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C0-6 alkyl, C0-6 alkyl heteroaryl, C0-6 alkylC3-6 alkyl, C0-6 alkyl C3-6cycloalkenyl, C0-6 alkyl C3-6 alkyl, C0-6 alkyl heterocyclyl C3-6, NR9R10, CONR9R10, NR9 (CO) R10, O (CO) R9, CO2R9, COR9, (SO2) NR9R10 , NR9 (SO2) R10, SO2R9, SOR9, OSO2R9 and SO3R9 wherein said C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C0-6alkyl, C0-6heteroaryl, C0-6-C3-6 alkyl alkyl, alkyl C0-6-C3-6 cycloalkenyl, C0-6 alkyl C3-6 alkyl and C0-6 alkyl C3-6 heterocyclyl may be optionally substituted with one or more E; or two R8 may together with the atoms to which they are attached form a cyclic or heterocyclic ring optionally substituted with one or more E; R9 and R10 are independently selected from hydrogen, C1-6 alkyl, fluoromethyl, difluoromethyl, trifluoromethyl, C2-6 alkenyl, C2-6 alkynyl, C0-6 alkyl, C0-6 alkyl, C0-6 alkyl, C0-6 alkyl, C0 alkyl -6-C3-6 cycloalkenyl, C0-6 alkyl-C3-6 cycloalkynyl, C0-6 alkyl heterocyclyl; or R9 and R10 may together form a 5- or 6-membered heterocyclic ring containing one or more heteroatoms selected from N, O or S; m = 0.1 or 2; n = 0.1, 2 or 3 p = 0.1, 2 or 3; q = 0.1, 2 or 3; t = 0, 1, 2 or 3; where one of n, p or q is at least 1; as a free base or a salt, solvate or solvate of a salt thereof acceptable for pharmaceutical use.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US81372806P | 2006-06-14 | 2006-06-14 | |
US89699407P | 2007-03-26 | 2007-03-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR061369A1 true AR061369A1 (en) | 2008-08-20 |
Family
ID=38831992
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP070102594A AR061369A1 (en) | 2006-06-14 | 2007-06-13 | PIRIMIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND THEM |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP2035423A1 (en) |
JP (1) | JP2009539973A (en) |
AR (1) | AR061369A1 (en) |
CL (1) | CL2007001733A1 (en) |
TW (1) | TW200815443A (en) |
UY (1) | UY30407A1 (en) |
WO (1) | WO2007145568A1 (en) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7763609B2 (en) | 2003-12-15 | 2010-07-27 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
US7592348B2 (en) | 2003-12-15 | 2009-09-22 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
US7700603B2 (en) | 2003-12-15 | 2010-04-20 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
ATE396990T1 (en) | 2004-07-28 | 2008-06-15 | Schering Corp | MACROCYCLIC INHIBITORS OF BETA SECRETASE |
RU2008100165A (en) | 2005-06-14 | 2009-07-20 | Шеринг Корпорейшн (US) | Aspartic Protease Inhibitors |
MX2007016183A (en) | 2005-06-14 | 2008-03-10 | Schering Corp | The preparation and use of compounds as protease inhibitors. |
TW200815349A (en) | 2006-06-22 | 2008-04-01 | Astrazeneca Ab | New compounds |
WO2008063114A1 (en) * | 2006-11-20 | 2008-05-29 | Astrazeneca Ab | Amino- imidazolones and their use as medicament for treating cognitive impairment alzheimer disease, neurodegeneration and dementia |
JP2011518224A (en) | 2008-04-22 | 2011-06-23 | シェーリング コーポレイション | Thiophenyl substituted 2-imino-3-methylpyrrolopyrimidinone compounds, compositions, and their use as BACE-1 inhibitors |
TW201020244A (en) | 2008-11-14 | 2010-06-01 | Astrazeneca Ab | New compounds |
EP2485590B1 (en) | 2009-10-08 | 2015-01-07 | Merck Sharp & Dohme Corp. | Pentafluorosulfur imino heterocyclic compounds as bace-1 inhibitors, compositions, and their use |
WO2011044187A1 (en) | 2009-10-08 | 2011-04-14 | Schering Corporation | Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
UA108363C2 (en) | 2009-10-08 | 2015-04-27 | IMINOTIADIASIADIOXIDE OXIDES AS BACE INHIBITORS, COMPOSITIONS THEREOF AND THEIR APPLICATIONS | |
EP2485920B1 (en) | 2009-10-08 | 2016-04-27 | Merck Sharp & Dohme Corp. | Pentafluorosulfur imino heterocyclic compounds as bace-1 inhibitors, compositions, and their use |
CA2824360C (en) * | 2011-03-01 | 2020-01-14 | Janssen Pharmaceutica Nv | 6,7-dihydro-pyrazolo[1,5-a]pyrazin-4-ylamine derivatives useful as inhibitors of beta-secretase (bace) |
US9145426B2 (en) | 2011-04-07 | 2015-09-29 | Merck Sharp & Dohme Corp. | Pyrrolidine-fused thiadiazine dioxide compounds as BACE inhibitors, compositions, and their use |
US9221839B2 (en) | 2011-04-07 | 2015-12-29 | Merck Sharp & Dohme Corp. | C5-C6 oxacyclic-fused thiadiazine dioxide compounds as BACE inhibitors, compositions, and their use |
KR20140054295A (en) | 2011-08-22 | 2014-05-08 | 머크 샤프 앤드 돔 코포레이션 | 2-spiro-substituted iminothiazines and their mono- and dioxides as bace inhibitors, compositions and their use |
CN104270945B (en) | 2012-03-19 | 2017-03-29 | 巴克老龄化研究所 | APP specific b ACE inhibitor (ASBI) and application thereof |
WO2014062549A1 (en) | 2012-10-17 | 2014-04-24 | Merck Sharp & Dohme Corp. | Tricyclic substituted thiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
WO2014062553A1 (en) | 2012-10-17 | 2014-04-24 | Merck Sharp & Dohme Corp. | Tricyclic substituted thiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
KR102220259B1 (en) | 2013-02-12 | 2021-02-25 | 버크 인스티튜트 포 리서치 온 에이징 | Hydantoins that modulate bace-mediated app processing |
JP7419865B2 (en) | 2020-02-17 | 2024-01-23 | 東ソー株式会社 | Aromatic halogen compounds, their uses, and manufacturing methods |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2005264917A1 (en) * | 2004-06-16 | 2006-01-26 | Wyeth | Diphenylimidazopyrimidine and -imidazole amines as inhibitors of B-secretase |
AU2006205127A1 (en) * | 2005-01-14 | 2006-07-20 | Wyeth | Amino-imidazolones for the inhibition of beta-secretase |
-
2007
- 2007-06-04 TW TW096119994A patent/TW200815443A/en unknown
- 2007-06-12 JP JP2009515344A patent/JP2009539973A/en active Pending
- 2007-06-12 WO PCT/SE2007/000571 patent/WO2007145568A1/en active Application Filing
- 2007-06-12 EP EP07748234A patent/EP2035423A1/en not_active Withdrawn
- 2007-06-12 UY UY30407A patent/UY30407A1/en not_active Application Discontinuation
- 2007-06-13 CL CL2007001733A patent/CL2007001733A1/en unknown
- 2007-06-13 AR ARP070102594A patent/AR061369A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP2035423A1 (en) | 2009-03-18 |
WO2007145568A9 (en) | 2008-12-11 |
UY30407A1 (en) | 2008-01-31 |
CL2007001733A1 (en) | 2008-01-25 |
WO2007145568A1 (en) | 2007-12-21 |
TW200815443A (en) | 2008-04-01 |
JP2009539973A (en) | 2009-11-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR061369A1 (en) | PIRIMIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND THEM | |
AR061371A1 (en) | AMINO - IMIDAZOLONAS AND ITS USE AS A MEDICINAL PRODUCT FOR ALZHEIMER'S DISEASE AND OTHER NEURODEGENERATIVE DISEASES. | |
AR061372A1 (en) | AMINO-IMIDAZOLES AND ITS USES AS MEDICINES FOR THE TREATMENT OF ALZHEIMER EVIL, DEMENTIA AND NEURODEGENERATION | |
AR061370A1 (en) | IMIDAZOPIRIMIDINE DERIVATIVES | |
AR066562A1 (en) | CONDENSED PIRROL DERIVATIVES; A PHARMACEUTICAL FORMULATION BASED ON THE COMPOUND AND ITS USE TO PREPARE MEDICINES | |
AR061564A1 (en) | DERIVATIVES OF ISOINDOLS, PHARMACEUTICAL COMPOSITIONS AND USES | |
ECSP088149A (en) | 3-ACILAMINOBENZANILIDAS INSECTICIDAS | |
ES2530943T3 (en) | Chromenone derivatives with antitumor activity | |
AR088449A1 (en) | BENZILINDAZOLES REPLACED | |
PE20130155A1 (en) | ARYLETINYL DERIVATIVES | |
ES2590504T3 (en) | N-cyclolamides as nematicides | |
AR062677A1 (en) | DERIVATIVES OF BIARIL-SULFONAMIDE, PRODUCTION PROCESSES AND PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND THEM | |
AR066561A1 (en) | IMIDAZOL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES | |
AR075854A1 (en) | BETA-SECRETASA INHIBITORS | |
AR073406A1 (en) | AMINODIHYDROTIAZINES FUSED WITH TETRAHYDROPIRANS, INHIBITORS OF BACE1 AND THE PRODUCTION OF ABETA AMILOID, PHARMACEUTICAL COMPOSITIONS CONTAINING THEMSELVES AND USES OF THE SAME FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES, TALES. | |
AR054560A1 (en) | SPIROPIPERIDINE AS BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | |
AR096979A1 (en) | DERIVATIVES OF PIRROL, ITS PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
AR061739A1 (en) | NEW NAFTALENIC DERIVATIVES, THEIR PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
AR082886A1 (en) | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
AR055878A1 (en) | CYCLOPROPANOCARBOXAMIDE DERIVATIVES | |
AR052568A1 (en) | DERIVATIVES OF PIRAZOLO-PYRIMIDINE AS ANGLOSTS OF MGLUR2 | |
CO6220949A2 (en) | PIRAZOLIC DERIVATIVES AS INHIBITORS OF THE 11 BETA -HSD1 | |
AR071323A1 (en) | HETEROCICLIC DERIVATIVES OF GLUCOQUINASE ACTIVATING PYRIDAZINONES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, METHOD OF PREPARATION AND USE OF THE SAME IN THE TREATMENT OF MELLITUS TYPE II DIABETES. | |
AR067613A1 (en) | PK-DNA INHIBITORS, USE AND SYNTHESIS OF THE SAME | |
CO6260009A2 (en) | DERIVATIVES OF ARYLOXYACETAMIDE BI-O SATURATED AND INSATURED TRICYCLES AND ITS USE AS FUNGICIDES |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |